Corbus to Present Scleroderma Drug at BIO CEO & Investor Conference
Emerging drug developer Corbus Pharmaceuticals Holdings, Inc. will be presenting its lead product candidate at the 17th Annual BIO CEO & Investor Conference taking place between February 9 and 10 at the Waldorf Astoria in New York. The investigational therapy, called Resunab, is meant to be a treatment for rare and life-threatening inflammatory and fibrotic conditions, including scleroderma.
CEO, Yuval Cohen, will host a lecture next Monday, February 9 at 11:30 a.m. EST, according to a press release from Corbus. During the presentation, Cohen will introduce a review about the clinical development of Resunab, and the company’s plans for the novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity, which is currently being investigated to treat Diffuse Cutaneous Systemic Sclerosis (scleroderma) and cystic fibrosis (CF).
Pre-clinical and phase 1 clinical trials already conducted by Corbus revealed that Resunab has a favorable safety profile as well as encouraging outcomes, as demonstrated by the results of the tests in in pre-clinical models of inflammation and fibrosis. The oral drug works by binding the CB2 receptor on immune cells, which triggers the inflammatory resolution process, resulting in the turning down of the chronic inflammation.
The company, which is dedicated to developing and commercializing novel therapeutics for the treatment of rare life-threatening inflammatory-fibrotic diseases with clear unmet medical needs, is planning to initiate the phase 2 studies to evaluate Resunab in both CF and scleroderma this year. In addition, the CEO of Corbus will provide more information on the clinical development of the oral drug at the conference.
The annual BIO CEO & Investor Conference is a major independent event designed to gather companies and investors working in the publicly-traded biotechnology field. The idea is to enable debate between institutional investors and senior biotechnology executives focused on emerging and current investment opportunities. Last year, the event included 1,820 partnering meetings, 149 company presentations, and 1,400 participants from whom about half were investors.
In addition to the presentation during the conference, the lecture will be available through live webcast on Corbus Pharmaceutical’s IR Calendar in the Investors section of the company’s website here, which will be accessible for a month. Yuval Cohen was also invited last December to present information on Resunab at the Virtual Investor Conferences, a live and interactive online event, a lecture that is also available on the website of the company.